Ticket Size
₹3,250
+150 YoY
Average order value increased from ₹3,100 at IPO to ₹3,250, driving revenue growth.
SATKARTARLIFE
Healthcare
15 May 2026
Sat Kartar Life Limited — Q4 FY26
Sat Kartar Life delivered a strong Q4 FY26 with revenue crossing ₹200 crore (up 23% YoY), EBITDA up 73%, and PAT up 74%.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Sat Kartar Life delivered a strong Q4 FY26 with revenue crossing ₹200 crore (up 23% YoY), EBITDA up 73%, and PAT up 74%. Growth was driven by D2C product expansion, higher ticket sizes (now ₹3,250), and the ramp-up of a new 30-bed hospital in Delhi. Management guided for product revenue of ₹300 crore in FY27 and ₹500 crore in FY28, supported by subsidiary Ajuni Life Sciences, US operations, and AI-driven efficiency gains. A strategic partnership with Gina aims to add 300 beds by FY27 and 1,000 by FY28, with a blended PAT margin target of 18-20% by H1 FY28. Key risk: hospital occupancy ramp-up may be slower than expected, given current utilization below 10% and pending insurance empanelment.
Key Numbers
Hospital Daily Revenue
₹50,000/day
N/A
Current daily revenue for the 30-bed hospital; break-even target is ₹1 lakh/day.
Subsidiary Revenue Target FY27
₹25-30 crore
+20x YoY
Subsidiaries (Ajuni Life Sciences, Plantommed) contributed ₹1.2 crore in FY26; target for FY27.
US Operations Revenue Target FY27
₹10-15 crore
N/A
US subsidiary expected to start contributing in FY27, pending RBI approval.
Management Guidance
Product revenue target of ₹300 crore for FY27
Management expects product revenue to reach ₹300 crore in FY27, driven by 25% organic growth, subsidiary ramp-up, and US operations.
Management guidance revenueProduct revenue target of ₹500 crore for FY28
Management targets ₹500 crore product revenue in FY28, supported by ticket size expansion and new product launches.
Management guidance revenuePAT margin target of 11-12% for FY27
Management expects PAT margin to improve from 8.5% to 11-12% in FY27 due to operating leverage.
Management guidance margins300 hospital beds operational by end of FY27
Management plans to have 300 beds operational by Q4 FY27, with 150-200 beds in collaboration with Gina.
Management guidance expansionKey Risks
Hospital occupancy ramp-up risk
Current hospital occupancy is below 10% and break-even is not yet achieved; slower-than-expected ramp-up could delay profitability.
high · analyst_questionRBI approval delay for US subsidiary
RBI approval for the US subsidiary is pending, which could delay equity infusion and operational scaling.
medium · analyst_questionHigh advertisement spend as % of revenue
Advertisement spend remains at 40% of revenue, limiting margin expansion; management expects only gradual reduction to 38%.
medium · management_commentaryWorking capital strain from hospital expansion
Hospital business requires significant working capital (50% of bed cost), and cash generation has been weak in FY26.
medium · data_observationNotable Quotes
We were a product company categorized as a product company. We will definitely remain as a product company primarily but yes we are moving into a full-fledged ecosystem into the complete sphere of the healthcare of Ayurveda.
Our few test results are very positive and we as since inception Satkatar always looks into the ROI. So AI has started giving ROI and improving our efficiency into the company.
I would instead of 100% I would recognize 15% but try to understand that this 15% would have not been with me for the next two years.
Frequently Asked Questions
What was Sat Kartar Life's revenue in Q4 FY26?
Sat Kartar Life reported revenue of ₹200 Cr in Q4 FY26, representing a +23% change compared to the same quarter last year.
What guidance did Sat Kartar Life management give for FY27?
Product revenue target of ₹300 crore for FY27: Management expects product revenue to reach ₹300 crore in FY27, driven by 25% organic growth, subsidiary ramp-up, and US operations. Product revenue target of ₹500 crore for FY28: Management targets ₹500 crore product revenue in FY28, supported by ticket size expansion and new product launches. PAT margin target of 11-12% for FY27: Management expects PAT margin to improve from 8.5% to 11-12% in FY27 due to operating leverage. 300 hospital beds operational by end of FY27: Management plans to have 300 beds operational by Q4 FY27, with 150-200 beds in collaboration with Gina.
What are the key risks for Sat Kartar Life in FY27?
Key risks include Hospital occupancy ramp-up risk — Current hospital occupancy is below 10% and break-even is not yet achieved; slower-than-expected ramp-up could delay profitability.; RBI approval delay for US subsidiary — RBI approval for the US subsidiary is pending, which could delay equity infusion and operational scaling.; High advertisement spend as % of revenue — Advertisement spend remains at 40% of revenue, limiting margin expansion; management expects only gradual reduction to 38%.; Working capital strain from hospital expansion — Hospital business requires significant working capital (50% of bed cost), and cash generation has been weak in FY26..
Did Sat Kartar Life meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Sat Kartar Life Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.